Acadia Pharmaceuticals (ACAD) said Tuesday it submitted a marketing authorization application to the European Medicines Agency for trofinetide to treat Rett syndrome in patients two years old and older.
Trofinetide is already approved in the US and Canada for Rett syndrome, a neurodevelopmental disorder, the company said.
Separately, Acadia Pharmaceuticals said it expects full-year 2025 net sales to top $1 billion for the first time in company history.
The company's shares were down 4.9% in recent trading.
Price: 17.03, Change: -0.87, Percent Change: -4.86
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。